Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.
暂无分享,去创建一个
[1] Peter Beighton,et al. de la Chapelle, A. , 1997 .
[2] J C Reed,et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. , 1995, Oncogene.
[3] K. Kinzler,et al. Mismatch repair deficiency in phenotypically normal human cells , 1995, Science.
[4] A. Bowcock,et al. Genetic instability in human ovarian cancer cell lines. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[5] R. Brown,et al. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. , 1994, Cancer research.
[6] W. Kaufmann,et al. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. , 1994, Cancer research.
[7] Y. Nakamura,et al. Frequent replication errors at microsatellite loci in tumors of patients with multiple primary cancers. , 1994, Cancer Research.
[8] A. Składanowski,et al. Relevance of interstrand DNA crosslinking induced by anthracyclines for their biological activity. , 1994, Biochemical pharmacology.
[9] John Calvin Reed,et al. Identification of a p53-dependent negative response element in the bcl-2 gene. , 1994, Cancer research.
[10] R. Fleischmann,et al. Mutation of a mutL homolog in hereditary colon cancer. , 1994, Science.
[11] D. Ward,et al. Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancer , 1994, Nature.
[12] M. Tilby,et al. Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. , 1994, Cancer research.
[13] Bert Vogelstein,et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells , 1993, Cell.
[14] P. Karran,et al. Incision at DNA G.T mispairs by extracts of mammalian cells occurs preferentially at cytosine methylation sites and is not targeted by a separate G.T binding reaction. , 1993, Biochemistry.
[15] R. Ozols,et al. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. , 1993, Cancer research.
[16] D. Housman,et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.
[17] J. Hickman,et al. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. , 1993, The EMBO journal.
[18] S. Korsmeyer,et al. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.
[19] B. Gallie,et al. Mutations of the p53 gene do not occur in testis cancer. , 1993, Cancer research.
[20] W. Thilly,et al. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[21] C. Purdie,et al. Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.
[22] G. Aquilina,et al. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage , 1993, Nature.
[23] Thea D. Tlsty,et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.
[24] M. Kastan,et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[25] J. Bartek,et al. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. , 1992, Journal of immunological methods.
[26] J. Hays,et al. Recombinagenic processing of UV-light photoproducts in nonreplicating phage DNA by the Escherichia coli methyl-directed mismatch repair system. , 1991, Genetics.
[27] J. Mattick,et al. 'Touchdown' PCR to circumvent spurious priming during gene amplification. , 1991, Nucleic acids research.
[28] K. McLaughlin,et al. Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line. , 1991, Cancer research.
[29] A. Eastman,et al. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. , 1991, The Journal of clinical investigation.
[30] R. Epstein,et al. Drug-induced DNA damage and tumor chemosensitivity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Lippard,et al. Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication. , 1990, Biochemistry.
[32] P. Walker,et al. Periodicity of DNA folding in higher order chromatin structures. , 1990, The EMBO journal.
[33] A. Pa,et al. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. , 1990 .
[34] S. Howell,et al. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. , 1990, Cancer cells.
[35] J. Jiricny,et al. A human 200-kDa protein binds selectively to DNA fragments containing G.T mismatches. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[36] S. Kaye,et al. The multidrug resistance phenotype. , 1988, British Journal of Cancer.
[37] S. Lippard,et al. Structural aspects of platinum anticancer drug interactions with DNA , 1987 .
[38] R C Young,et al. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. , 1987, Cancer research.
[39] A. Tulpule,et al. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[40] T. Kao,et al. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. , 1985, Nucleic acids research.
[41] R. Ozols,et al. Reversal of adriamycin resistance by verapamil in human ovarian cancer. , 1984, Science.
[42] S K Carter,et al. Adriamycin. A new anticancer drug with significant clinical activity. , 1974, Annals of internal medicine.